|
\( \widehat{P}\left(\mathrm{sBMS}\right) \)
|
9.7
|
3.6 – 18.0
|
5.0
|
2.6 – 9.5
|
|
\( \widehat{P}\left(\mathrm{sDES}\right) \)
|
81.8
|
74.3 – 87.5
|
85.3
|
81.4 – 87.7
|
|
\( \widehat{P}\left(\mathrm{sCABG}\right) \)
|
8.5
|
7.5 – 9.0
|
9.6
|
7.8 – 10.6
|
|
\( \widehat{P}\left(\mathrm{Restenosis}\left|\mathrm{sBMS}\right.\right) \)
|
0.1
|
0.0 – 0.0
|
0.0
|
0.0 – 0.0
|
|
\( \tilde{P}\left(\mathrm{Restenosis}\left|\mathrm{sDES}\right.\right) \)
|
7.6
|
6.7 – 7.9
|
7.0
|
6.1 – 7.5
|
|
\( \widehat{P}\left(\mathrm{Restenosis}\right) \)
|
6.4
|
5.5 – 6.9
|
6.2
|
5.3 – 6.6
|
|
\( \tilde{P}\left(\mathrm{Hazard}\left|\mathrm{sBMS}\right.\right) \)
|
0.0
|
0.0 – 0.0
|
1.5
|
0.0 – 16.7
|
|
\( \widehat{P}\left(\mathrm{Hazard}\left|\mathrm{sDES}\right.\right) \)
|
3.2
|
2.1 – 3.5
|
8.2
|
7.2 – 9.5
|
|
\( \widehat{P}\left(\mathrm{Hazard}\right) \)
|
3.3
|
2.5 – 3.8
|
7.9
|
6.9 – 9.5
|
|
Baseline estimate for P(Adverse effect)
|
14.1
|
12.6 – 14.5
|
18.8
|
17.6 – 19.6
|
|
Proposed estimate for P(Adverse effect)
|
9.7
|
8.3 – 10.6
|
14.1
|
12.4 – 15.6
|
|
ΔP(Adverse effect)
|
4.4
|
3.5 – 5.4
|
4.7
|
3.4 – 5.5
|
